{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Abdominal pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Alkaline phosphatase increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Anemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Anorexia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Back pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Blood bilirubin increased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"CD4 lymphocytes decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Diarrhea"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Fatigue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"Febrile neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Fever"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Gastrointestinal disorders - Other, specify"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypercalcemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hyperglycemia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Hypotension"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Infections and infestations - Other, specify"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Leukocytosis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lung infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Lymph gland infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":"Lymphocyte count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Mucositis oral"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"Neutrophil count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"Platelet count decreased"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Rash maculo-papular"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Sepsis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Skin and subcutaneous tissue disorders - Other"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Skin infection"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Toxic epidermal necrolysis"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Treatment related secondary malignancy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"White blood cell decreased"}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"Incidence of toxicity as assessed by the Common Terminology Criteria for Adverse Events version 4.0. For each patient, worst grade of each event type is reported. Grade 3 = Severe, Grade 4 = Life-threatening, Grade 5 = Fatal.","groups":[{"description":"Patients receive MLN8237 (alisertib) PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity","id":"OG000","title":"MLN8237"}],"paramType":"NUMBER","populationDescription":"Eligible patients who had received any treatment were included in the adverse event summaries. Any CTCAE 4.0 event of Grade 3 (severe), Grade 4 (life threatening), or Grade 5 (fatal) which deemed to be related to protocol treatment are included.","reportingStatus":"POSTED","timeFrame":"Up to 1 year after registration","title":"To Evaluate the Safety and Tolerability of MLN8237 (Number of With Grade 3 Through Grade 5 Adverse Events That Are Related to MLN8237)","type":"SECONDARY","unitOfMeasure":"Participants"}